Stocktoria
Theravance Biopharma, Inc. TBPH
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-05-16
Theravance Biopharma, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -3.4% | -72.9% | -97.6% | -179.1% | -466.1% |
| Net margin | 98.5% | -87.6% | -96.1% | 1698.5% | -360.6% |
| Return on assets | 21.8% | -15.9% | -14.4% | 143.6% | -53.2% |
| Return on equity | 35.7% | -32.1% | -25.9% | 197.4% | 58.9% |
| Debt / equity | — | — | 0.00× | — | -1.82× |
| Current ratio | 10.93 | 5.02 | 5.39 | 12.31 | 4.26 |
| Revenue growth | 66.9% | 12.1% | 11.8% | -7.2% | -23.0% |
Source: SEC EDGAR filings · CIK 0001583107 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.